Primer día de la última semana de enero... ¿Comenzamos? Feliz inicio de semana para todos y todas 🙂 https://t.co/bBNlkwLShw
In a clinical trial that ended prematurely, where pretreatment was guided either by vision loss or vision loss and/or signs of disease activity on OCT, both groups demonstrated gains at 12 months, with a trend in favor of OCT-guided retreatment. https://
RT GUARDiONHealth: Functional versus functional and anatomical criteria-guided ranibizumab treatment in patients with neovascular age-related macular degeneration – results from the randomized, phase IIIb OCTAVE study https://t.co/fEGN3YYJ3k
Functional versus functional and anatomical criteria-guided ranibizumab treatment in patients with neovascular age-related macular degeneration – results from the randomized, phase IIIb OCTAVE study https://t.co/HOpTPYxrsR